A reduction in IL-1β, IL-6 and TNF-α signaling was found to be effective at inhibiting macrophages in chronic intestinal inflammation, thereby indicating that IL-1β, IL-6 and TNF-α are potential therapeutic targets in IBD [30,31]. This evidence concerns the gene IL1B and inflammatory bowel disease.